Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Trevogrumab-Part A, Trevogrumab-Part B and Part C
Trevogrumab · 1 trial · 1 indication
Part A
Part A
Part B
Part B
Part B
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Part A Randomized 1:1 |
| Trevogrumab | EXPERIMENTAL | Part A Randomized 1:1 |
| Arm A0 | EXPERIMENTAL | Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm A1 | EXPERIMENTAL | Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 |
| Arm B0 | EXPERIMENTAL | Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm B1 | EXPERIMENTAL | Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 |
| Arm C0 | EXPERIMENTAL | Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm C1 | EXPERIMENTAL | Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 |
| Arm D0 | EXPERIMENTAL | Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 |
| Arm D1 | EXPERIMENTAL | Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 |
| Arm 1 | EXPERIMENTAL | Part C Sema and SC placebo Randomized 1:2:2 |
| Arm 2 | EXPERIMENTAL | Part C Sema and SC low dose trevo Randomized 1:2:2 |
| Arm 3 | EXPERIMENTAL | Part C Sema and SC moderate dose trevo Randomized 1:2:2 |
| Name | Type | Description |
|---|---|---|
| Trevogrumab-Part A | DRUG | Administered IV or SC in Part A |
| Trevogrumab-Part B and Part C | DRUG | Administered SC in Part B, Part C |
| Garetosmab | DRUG | Administered IV in Part B |
| Semaglutide | DRUG | Administered SC in Part B and Part C |
| Matching Placebo-Part A | DRUG | Administered IV or SC in Part A |
| Matching Placebo-Trevogrumab | DRUG | Administered SC in Part B and Part C |
| Matching Placebo-Garetosmab | DRUG | Administered IV in Part B |
Key Inclusion Criteria Part A 1. Male or female participants age ≥18 to ≤55 years of age at the time of screening 2. BMI ≥18 and ≤32 kg/m2, at the screening visit Part B and Part C 3. Male or female participants ≥18 to ≤80 years of age at the time of screening 4. BMI ≥30 kg/m2, at the screenin...
Top 20 of 32 competitors